Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ataş Ünal, Salim Ozan, Iltar Utku, Yücel Orhan Kemal, Küçükdiler Eroğlu Ayşe Hilal, Aslan Vedat, Yıldırım Murat, Dedeoğlu Özen, Seçilmiş Sema, Ulaş Turgay, Deveci Burak, Karaman Gulsaran Sedanur, Gedük Ayfer, Yaman Fatih, Pınar İbrahim Ethem, Maral Senem, Sarıcı Ahmet, Çelik Serhat, Oğul Hande, Gülkan Özkan Sıdıka, Gemici Aliihsan, Güneş Ahmet Kurşat, Tombak Anil, Yavaşoğlu İrfan, Karakuş Volkan, Cömert Melda, Toptaş Tayfur, Dal Mehmet Sinan, Saba Rabin, Kırkızlar Hakkı Onur, Mehtap Özgür, Gündüz Eren, Özkalemkaş Fahir, Albayrak Murat, Berber İlhami, Keklik Muzaffer, Güler Nil, Özkan Hasan Atilla, Sevindik Ömür Gökmen, Bolaman Zahit, Kurtoğlu Erdal, Aylı Meltem, Fıratlı Tuğlular Tülin, Altuntaş Fevzi, Ündar Levent
Аннотация
MATERIALS AND METHODS: Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of the pPCL diagnosis, 20% leukocytes or ≥2x109/L plasma cells in the peripheral blood was used as a diagnostic criterion.
RESULTS: The median age of the patients was 58 years and 23 (43.4%) patients were over 65 years of age. For first-line treatment, PI or IMID alone was used by 31 (58.5%) patients, and PI and IMID were used simultaneously by 15 (28.3%) patients. Additionally, 21 (39.6%) patients received transplantation and 13 (24.5%) patients received maintenance treatment. The median progression-free survival was 4 (range: 1-42) months. When patients whose primary disease was refractory to first-line therapy were excluded, the duration of treatment was 6.5 months. The median OS was 15 months with a median follow-up duration of 15 months. Only 7 (13.2%) of the patients were alive at the last follow-up visit. Those with higher β2-microglobulin levels and International Staging System stage 3 and non-transplant patients receiving first-line treatment had shorter OS (p=0.005, p=0.02, and p=0.008, respectively). The concomitant use of PIs and IMIDs, the addition of chemotherapy to induction therapy, and the response to induction therapy or maintenance therapy did not affect OS.
CONCLUSION: In this study, as in previous similar studies, we could not see an increased survival trend in pPCL, which is observed in MM. New studies are needed for pPCL, which is likely to increase with new diagnostic criteria, based on current agents and information from MM.